Collection of Bone Marrow From Donors Treated With or Without Filgrastim

Inclusion Criteria: * Appropriately human leukocyte antigen (HLA)-matched (HLA, A, B, DRB1 identical or antigen mismatched \[i.e., 5/6 or 6/6 antigens matched\]) sibling of the bone marrow recipient enrolled on COG-ASCT0631 * Adequate size relative to the recipient (i.e., harvesting the maximum of 20 cc/kg from the donor would result in a bone marrow graft that will provide an adequate cell and volume dose to the recipient, in the opinion of the treating physician) * Enrolled on the COG Umbrella Long-Term Follow-Up Study COG-ALTE05N1 * Not pregnant or nursing * No human immunodeficiency virus (HIV) positivity * No sickle cell trait or sickle cell anemia/disease * Not at an increased risk from bone marrow donation after filgrastim administration due to a pre-existing medical condition, as determined by an independent physician separate from the research team * None of the following: * Active infection, especially pulmonary * Splenomegaly or a history of splenic injury * Active or recent pulmonary disease (i.e., pneumonia within the past 4 weeks) * A condition that would make the donor unsuitable to donate, as determined by an independent physician separate from the research team * No autoimmune disease